Burger King Is Bracing for the GLP-1 Effect on Fast Food, Even Though Sales Haven’t Budged Yet

Burger King is already thinking ahead. The company wants to prepare for a future where weight loss drugs change how Americans eat. Tom Curtis runs the chain’s U.S. and Canada business. He laid out the strategy in a recent interview with NBC News.

His take is simple. GLP-1 drugs will matter for the restaurant industry. Maybe not today, but soon.

Here’s the thing, though. Burger King’s numbers haven’t shown that shift yet. Whopper sales are holding steady. Curtis has said as much himself.

So why prepare for something that hasn’t happened? These drugs work fast on the body. Once enough people start using them, the effects on eating habits tend to follow quickly too.

Here’s a quick refresher on how they work. Medications like semaglutide and tirzepatide copy a hormone your body already makes. That hormone helps regulate appetite and blood sugar. The drugs slow digestion and help you feel full sooner. As a result, people eat less and snack less.

The FDA has approved several versions of these drugs. They treat type 2 diabetes and support chronic weight management. They’re prescription-only, so you can’t just buy them over the counter. A doctor has to prescribe them, and patients usually need regular check-ins while taking them.

Back to Burger King’s playbook. Curtis said the chain is testing smaller items. Think mini Whopper bites and protein-based bowls. The goal isn’t to shrink the menu. Instead, the company wants to keep its usual variety but in portions that fit someone who simply isn’t as hungry anymore.

That’s a real shift for a chain built on big burgers and combo meals. Still, Curtis framed it as staying ahead of the curve. He didn’t describe it as reacting to a crisis.

The numbers explain why this matters. Roughly one in eight American adults now takes a GLP-1 drug, based on recent survey data. Among users who eat less, most also report snacking less. That’s not a small shift. Snacking has driven fast food and packaged food revenue for decades.

Other companies are watching closely too. Most haven’t seen major damage to their sales yet, but they’re paying attention anyway.

A couple of factors could speed things up. Medicare is piloting a program to expand GLP-1 coverage. That move alone could open access to millions more patients. Meanwhile, drugmakers face real pressure over the cost of treatment from regulators, insurers, and competitors.

If both trends continue, lower prices and wider coverage together- adoption could climb faster than restaurant chains currently expect.

It’s also worth noting that these medications carry real considerations. Gastrointestinal side effects are common. Doctors generally recommend pairing the drugs with dietary guidance rather than using them alone. Researchers are still studying the long-term picture, especially for people who eventually stop treatment.

For now, Burger King’s approach looks more like insurance than panic. The company is testing smaller formats. It’s watching the data closely. And it’s staying ready in case the shift finally reaches its sales numbers. So far, though, that shift hasn’t arrived.